Calcium antagonists. Drug interactions of clinical significance
- PMID: 7495502
- DOI: 10.2165/00002018-199513030-00003
Calcium antagonists. Drug interactions of clinical significance
Abstract
The interaction of calcium antagonists, including the dihydropyridine calcium antagonists (e.g. nifedipine), verapamil and diltiazem, with drugs from other classes has major clinical ramifications as the use of drug combinations increases in frequency. Combinations are used in the treatment of disorders ranging from hypertension to cardiac rhythm disturbances, angina pectoris and peripheral vasospastic disease. In this era of organ transplantation, drugs like cyclosporin are coming into potential conflict with an ever-growing list of drugs. Drug combinations used as part of long term therapies are also making their appearance in toxic drug reactions, including antituberculous and anticonvulsant agents. Bronchodilators and H2-blockers also fall into this category of potential culprits of combined drug toxicity, and the interactions of calcium antagonists with beta-blockers and antiarrhythmic agents are also becoming a matter of concern.
Similar articles
-
Calcium channel blockers: spectrum of side effects and drug interactions.Acta Pharmacol Toxicol (Copenh). 1986;58 Suppl 2:119-30. doi: 10.1111/j.1600-0773.1986.tb02527.x. Acta Pharmacol Toxicol (Copenh). 1986. PMID: 2872768 Review.
-
Pharmacokinetic interactions with calcium channel antagonists (Part II).Clin Pharmacokinet. 1991 Dec;21(6):448-60. doi: 10.2165/00003088-199121060-00005. Clin Pharmacokinet. 1991. PMID: 1782739 Review.
-
Drug interactions with neuromuscular blockers.Drug Saf. 1996 Oct;15(4):261-73. doi: 10.2165/00002018-199615040-00004. Drug Saf. 1996. PMID: 8905251 Review.
-
In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II).Cancer Res. 1989 Jun 1;49(11):2844-50. Cancer Res. 1989. PMID: 2720644
-
Calcium antagonists. Mechanisms, therapeutic indications and reservations: a review.Q J Med. 1984 Winter;53(209):1-16. Q J Med. 1984. PMID: 6324268 Review.
Cited by
-
Clinically Important Drug-Drug Interactions Between Antiarrhythmic Drugs and Anticoagulants.J Innov Card Rhythm Manag. 2019 Mar 15;10(3):3552-3559. doi: 10.19102/icrm.2019.100304. eCollection 2019 Mar. J Innov Card Rhythm Manag. 2019. PMID: 32494414 Free PMC article. Review.
-
Treatment of esophageal motility disorders based on the chicago classification.Curr Treat Options Gastroenterol. 2014 Dec;12(4):441-55. doi: 10.1007/s11938-014-0032-9. Curr Treat Options Gastroenterol. 2014. PMID: 25263532
-
Potentially significant drug interactions of class III antiarrhythmic drugs.Drug Saf. 2003;26(6):421-38. doi: 10.2165/00002018-200326060-00004. Drug Saf. 2003. PMID: 12688833 Review.
-
Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives.Drug Saf. 2003;26(10):707-20. doi: 10.2165/00002018-200326100-00004. Drug Saf. 2003. PMID: 12862505 Review.
-
Calcium Channel Blocker Toxicity: A Practical Approach.J Multidiscip Healthc. 2022 Aug 30;15:1851-1862. doi: 10.2147/JMDH.S374887. eCollection 2022. J Multidiscip Healthc. 2022. PMID: 36065348 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources